Chemotherapy in elderly patients with resected stage II-IIIA lung cancer: Age alone is not a contraindication to treatment

BMJ (Online)

Volumn 343, Issue 7817, 2011, Pages

  Fervers, Béatrice ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; EDITORIAL; GERIATRIC PATIENT; HUMAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; FEMALE; LUNG TUMOR; MALE; NOTE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PLATINUM COMPOUNDS;

EID: 84859008579     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4104     Document Type: Editorial

References (12)

1. Wisnivesky JP, Smith CB, Packer S, Strauss GM, Lurslurchachai L, Federman A, et al. Survival and risk of adverse events in elderly patients receiving postoperative adjuvant chemotherapy for resected stage II-IIIA lung cancer: observational cohort study. BMJ 2011;343:d4013.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. (Pubitemid 38101630)
4. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. (Pubitemid 41007845)
5. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27. (Pubitemid 44283661)
6. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
7. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77.
8. National Institute for Health and Clinical Excellence. Lung cancer: the diagnosis and treatment of lung cancer. 2011. http://guidance.nice.org.uk/CG121.
9. Asmis T, Ding K, Seymour L, Shepherd FA, Leighl NB, Whitehead M, et al. Age and comorbidities as independent prognostic factors in the treatment of non-small cell lung cancer: a review of the National Cancer Institute of Canada Trials Group Trials. J Clin Oncol 2008;26:53-8.
10. Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR10. J Clin Oncol 2007;25:1553-61. (Pubitemid 46733082)
11. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007 ;25:5570-7.
12. Avery EJ, Kessinger A, Ganti AK. Therapeutic options for elderly patients with advanced non-small cell lung. Cancer Treat Rev 2009;35:340-4.